Willis Investment Counsel’s Sanofi SNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.7M | Sell |
602,300
-1,700
| -0.3% | -$76K | 1.22% | 32 |
|
|
2026
Q1 | $29.1M | Hold |
604,000
| – | – | 1.59% | 24 |
|
|
2025
Q4 | $29.3M | Buy |
604,000
+47,300
| +8% | +$2.34M | 1.51% | 21 |
|
|
2025
Q3 | $26.3M | Buy |
556,700
+56,500
| +11% | +$2.73M | 1.44% | 26 |
|
|
2025
Q2 | $24.2M | Buy |
500,200
+179,600
| +56% | +$9.18M | 1.41% | 28 |
|
|
2025
Q1 | $17.8M | Buy |
320,600
+84,900
| +36% | +$4.6M | 1.2% | 36 |
|
|
2024
Q4 | $11.4M | Hold |
235,700
| – | – | 0.75% | 58 |
|
|
2024
Q3 | $13.6M | Hold |
235,700
| – | – | 0.88% | 50 |
|
|
2024
Q2 | $11.4M | Hold |
235,700
| – | – | 0.79% | 54 |
|
|
2024
Q1 | $11.5M | Hold |
235,700
| – | – | 0.79% | 52 |
|
|
2023
Q4 | $11.7M | Sell |
235,700
-600
| -0.3% | -$29.3K | 0.83% | 53 |
|
|
2023
Q3 | $12.7M | Hold |
236,300
| – | – | 0.96% | 41 |
|
|
2023
Q2 | $12.7M | Hold |
236,300
| – | – | 0.83% | 49 |
|
|
2023
Q1 | $12.9M | Hold |
236,300
| – | – | 0.84% | 51 |
|
|
2022
Q4 | $11.4M | Hold |
236,300
| – | – | 0.73% | 60 |
|
|
2022
Q3 | $8.98M | Sell |
236,300
-34,900
| -13% | -$1.56M | 0.65% | 61 |
|
|
2022
Q2 | $13.6M | Sell |
271,200
-4,400
| -2% | -$234K | 0.83% | 52 |
|
|
2022
Q1 | $14.1M | Sell |
275,600
-4,800
| -2% | -$248K | 0.75% | 57 |
|
|
2021
Q4 | $14M | Sell |
280,400
-3,900
| -1% | -$193K | 0.74% | 57 |
|
|
2021
Q3 | $13.7M | Hold |
284,300
| – | – | 0.78% | 51 |
|
|
2021
Q2 | $15M | Buy |
284,300
+6,700
| +2% | +$350K | 0.88% | 46 |
|
|
2021
Q1 | $13.7M | Buy |
277,600
+134,300
| +94% | +$6.45M | 0.83% | 44 |
|
|
2020
Q4 | $6.96M | Buy |
143,300
+125,300
| +696% | +$6.18M | 0.48% | 65 |
|
|
2020
Q3 | $903K | Sell |
18,000
-198,600
| -92% | -$10.2M | 0.08% | 95 |
|
|
2020
Q2 | $11.1M | Sell |
216,600
-279,800
| -56% | -$13.6M | 0.86% | 47 |
|
|
2020
Q1 | $21.7M | Sell |
496,400
-3,900
| -0.8% | -$187K | 1.8% | 18 |
|
|
2019
Q4 | $25.1M | Sell |
500,300
-28,500
| -5% | -$1.34M | 1.62% | 32 |
|
|
2019
Q3 | $24.5M | Buy |
528,800
+76,800
| +17% | +$3.31M | 1.64% | 28 |
|
|
2019
Q2 | $19.6M | Buy |
452,000
+163,580
| +57% | +$6.96M | 1.32% | 39 |
|
|
2019
Q1 | $14.9M | Sell |
288,420
-163,580
| -36% | -$7.01M | 1.03% | 47 |
|
|
2018
Q4 | $19.6M | Sell |
452,000
-400
| -0.1% | -$17.6K | 1.46% | 23 |
|
|
2018
Q3 | $20.2M | Buy |
452,400
+19,000
| +4% | +$812K | 1.39% | 28 |
|
|
2018
Q2 | $17.3M | Buy |
433,400
+36,100
| +9% | +$1.42M | 1.28% | 28 |
|
|
2018
Q1 | $15.9M | Buy |
397,300
+372,000
| +1,470% | +$15.5M | 1.23% | 35 |
|
|
2017
Q4 | $1.09M | Buy |
25,300
+16,200
| +178% | +$747K | 0.08% | 112 |
|
|
2017
Q3 | $453K | Buy |
+9,100
| New | +$440K | 0.03% | 116 |
|
|
2017
Q2 | – | Sell |
-440,800
| Closed | -$19.9M | – | 125 |
|
|
2017
Q1 | $19.9M | Sell |
440,800
-10,900
| -2% | -$462K | 1.5% | 17 |
|
|
2016
Q4 | $18.3M | Buy |
451,700
+77,600
| +21% | +$3.06M | 1.36% | 28 |
|
|
2016
Q3 | $14.3M | Buy |
+374,100
| New | +$15M | 1.14% | 38 |
|
Other funds holding SNY
MIP
BIP
Willis Investment Counsel's SNY Position: Q2 2026 in Review
Willis Investment Counsel reduced its Sanofi (SNY) stake by 0.28% in Q2 2026, selling an estimated $76K and leaving 602,300 shares worth $25.7M. The position accounts for 1.22% of the portfolio, ranked #32.
Willis Investment Counsel first reported a position in SNY in Q3 2016 and has held it in 39 quarters since. The position peaked at $29.3M in Q4 2025. 716 funds tracked by Wall St. Rank hold SNY as of Q2 2026.
- Willis Investment Counsel held 602,300 shares of Sanofi worth $25.7M as of Q2 2026.
- Willis Investment Counsel sold 1,700 Sanofi shares in Q2 2026, an estimated $76K.
- Sanofi made up 1.22% of Willis Investment Counsel's portfolio in Q2 2026, its #32 holding.
- Willis Investment Counsel first reported a position in Sanofi in Q3 2016 and has held it in 39 quarters since.
- Willis Investment Counsel's Sanofi position peaked at $29.3M in Q4 2025.
- 716 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.
Based on Willis Investment Counsel's 13F filing for Q2 2026, filed 3 Aug 2026.